A national survey of 434 cannabis dispensary staff across 34 states finds that budtenders and managers, not clinicians, deliver most cannabis safety guidance. Over a quarter of staff do not believe cannabis is addictive, and state-level regulations appear to have little measurable impact on what advice customers actually receive about medical and psychiatric risks.

As cannabis retail expands across the United States, dispensary staff have become de facto health counselors for millions of consumers managing chronic pain, anxiety, PTSD, and other complex conditions. Yet the training, beliefs, and regulatory oversight of these staff remain poorly understood. When more than one in four front-line cannabis advisors doubts that the substance they sell is addictive, and state-level policy frameworks appear to do little to change the counseling delivered, the implications for patient safety, harm reduction, and clinical coordination demand close attention from both clinicians and policymakers.

Cannabis dispensary staff have become the primary point of contact for millions of Americans seeking guidance on cannabis dosing, safety, and potential interactions with existing medical conditions. Unlike pharmacists dispensing conventional medications, these staff members operate in a fragmented regulatory landscape, and the degree to which state-level cannabis policy shapes their counseling practices is poorly understood. This study used the Medical Cannabis Law Stringency Scale (MCLaSS), a composite measure of how medically oriented a state’s cannabis program is, alongside adult-use legalization status, to examine whether policy environments predict what dispensary staff say they would advise customers with complex medical and psychiatric comorbidities. The survey instrument, developed through expert consensus and industry piloting, was distributed to 6,721 dispensaries across 34 states.

Of the 434 eligible respondents, the majority reported that they would encourage customers with medical comorbidities to inform their healthcare providers about cannabis use. However, state medicalization score was statistically associated with only two of many tested outcomes: encouraging healthcare provider notification for medical conditions (OR 1.2, 95% CI 1.0 to 1.4) and reduced likelihood of recommending cannabis for cannabis use disorder (OR 0.8, 95% CI 0.7 to 1.0). Adult-use legalization was associated with recommending traditional care over cannabis for serious mental illness (OR 2.2, 95% CI 1.1 to 4.7). Perhaps most strikingly, 26% of respondents did not believe cannabis is addictive, and fewer than half reported having encountered a customer with cannabis use disorder. The authors note that these findings are limited by a 7.1% response rate, self-report bias, no correction for multiple comparisons, and the cross-sectional design. They call for observational studies of actual dispensary counseling and standardized staff training programs.

Between the Counter and the Clinic: Who Is Really Counseling Cannabis Consumers?

In most U.S. states where cannabis is legal, the person most likely to advise you on dosing, drug interactions, and safety for your medical condition isn’t your doctor. It’s the person behind the dispensary counter. A new national survey asks whether they’re equipped for that role, and the answer is complicated. This study by Slawek and colleagues does something genuinely valuable: it maps, for the first time at national scale, the counseling attitudes of the workforce that actually interacts with cannabis consumers at the point of purchase. What it reveals is a structural disconnect. Healthcare providers certify patients for cannabis but rarely guide dosing or monitor for adverse interactions. Dispensary staff fill that void, yet the vast majority lack clinical training, and more than a quarter do not believe the product they sell can be addictive. The study correctly identifies this as a problem that state regulation has not solved. The MCLaSS score, a measure of how “medicalized” a state’s cannabis program is on paper, was associated with only two of many tested counseling behaviors, and the effect sizes were modest. This is akin to judging a pharmacist’s counseling quality by the average rigor of their state’s pharmacy board regulations, even though the individual store’s training, chain-level policies, and the pharmacist’s own knowledge may matter far more. The regulatory framework exists on paper; the question is whether it reaches the counter.

The paper’s chief methodological limitation is one that clinicians should understand clearly. Dozens of regression models were tested simultaneously, and no adjustment for multiple comparisons was applied. When you run that many statistical tests, finding a few “significant” results by chance alone is expected. The three associations the authors highlight may be real, but they may also be statistical noise. A more conservative analytical approach might have yielded no significant policy associations at all, which would have been an equally important finding. Beyond the statistics, there is a deeper issue: the study measures what dispensary staff say they would do, not what they actually do. Asking someone what they would eat if they were trying to be healthy, then assuming that is what they actually eat, illustrates the gap between intention and action. Mystery shopper studies or recorded encounters would bring us far closer to the truth. The 26% who doubt cannabis is addictive are described as a group, but we don’t learn who they are. Are they disproportionately budtenders? Located in particular states? Newer to the industry? These are questions the data could have begun to answer.

What would I tell a patient? When you visit a dispensary, the staff member advising you may genuinely want to help, but they may not know about cannabis interactions with your medications, may not recognize signs of dependence, and likely do not know your full medical history. Please loop your doctor in, and if your doctor is not comfortable discussing cannabis, push for that conversation. What would I tell a colleague? This survey is a useful wake-up call. The people our patients are actually consulting about cannabis dosing and safety have significant knowledge gaps around addiction, and state regulations do not seem to fix this. We cannot outsource cannabis counseling to dispensaries and call it done. The durable lesson here extends beyond cannabis: the existence of a regulatory framework does not guarantee that the intended behavior change occurs at the individual level. Measurement of actual practice, not just policy structure, is essential for evidence-based cannabis safety policy.

This study occupies an early and necessary position in the research arc on cannabis retail counseling. Prior work has characterized individual dispensary interactions in specific states or focused on product recommendations, but this is among the first to examine the relationship between state policy environments and staff-reported counseling across a broad geographic sample. It establishes a descriptive baseline rather than a definitive causal account. Its hypothesis-generating value is genuine: it identifies where the gaps are and suggests where interventions might be directed, even if it cannot yet tell us what works.

From a pharmacological and safety standpoint, the finding that dispensary staff frequently recommend cannabis for conditions where clinical evidence is mixed or where cannabis may pose risks (such as serious mental illness or active substance use disorders) warrants concern. Clinicians should be aware that patients may arrive at appointments having received dispensary guidance that conflicts with clinical evidence, particularly around psychiatric conditions and addiction risk. The most concrete actionable step emerging from these data is for primary care and specialty providers to proactively and nonjudgmentally ask patients about dispensary-sourced cannabis advice, treat those conversations as a routine part of medication reconciliation, and provide clear, evidence-based guidance where dispensary staff cannot.

This is a cross-sectional survey study using multivariable logistic regression, positioned in the lower-to-middle tier of the evidence hierarchy. It can identify associations and generate hypotheses but cannot establish causal relationships. The single most important inference constraint is that all outcomes are self-reported intentions rather than observed behaviors, meaning the study measures what staff say they would do, not what they actually do in practice. This distinction is critical for interpreting every finding.

This study extends prior state-specific dispensary research by providing a multi-state, multi-role snapshot of counseling attitudes. It aligns with earlier findings from Haug and colleagues that dispensary staff frequently make health claims beyond the evidence base, and with the MCLaSS framework developed by Richard et al. (2021), which first operationalized the concept of medical cannabis law stringency. However, the weak associations between MCLaSS scores and counseling behaviors challenge the assumption that more medicalized programs necessarily produce safer dispensary practices. The study also reinforces a growing body of literature suggesting that CUD remains under-recognized outside of formal clinical settings, a finding consistent with SAMHSA epidemiological data showing that most individuals with CUD do not receive treatment.

The most consequential analytic choice was the decision not to adjust for multiple comparisons across dozens of simultaneously tested regression models. Had the authors applied a Bonferroni correction or false discovery rate adjustment, it is plausible that none of the three nominally significant associations (MCLaSS with HCP notification, MCLaSS with CUD recommendations, and adult-use with SMI referral) would have survived. Pre-specifying a small number of primary outcomes would have strengthened the confirmatory value of the significant findings. Additionally, incorporating store-level or chain-level training variables, rather than relying solely on state-level policy scores, might have explained substantially more variance in counseling behavior and could have shifted the interpretation from “policy doesn’t matter” to “policy matters less than local training.”

The most likely overinterpretation is concluding that “more medicalized states have safer dispensary counseling.” The MCLaSS score was associated with only two of many tested outcomes, with modest effect sizes, and the study cannot establish causality. A related misreading is treating the 26% figure as a precise national estimate of dispensary staff who doubt cannabis is addictive. Because this comes from a convenience sample with a 7.1% response rate, the true prevalence in the dispensary workforce is unknown and could be higher or lower depending on the direction of selection bias. Finally, this study should not be read as evidence that dispensary staff are providing dangerous counseling across the board. Most respondents reported referring customers to healthcare providers. The concern is the significant minority who do not, and the fundamental uncertainty about whether stated intentions match real-world behavior.

This study contributes a rare national baseline characterizing cannabis dispensary staff counseling attitudes and their weak association with state policy environments. It does not establish that regulations cause safer counseling, nor does it confirm that reported intentions reflect actual practice. Its most durable contribution is the descriptive finding that significant knowledge gaps around cannabis addiction exist among front-line dispensary staff. For now, clinicians should proactively engage patients about dispensary-sourced advice, and policymakers should recognize that regulatory frameworks without validated training mandates may be insufficient.

Should I trust the advice I get at a cannabis dispensary?

Dispensary staff often have product knowledge and may genuinely want to help, but this survey found that most lack formal clinical training and a significant minority hold misconceptions about cannabis addiction. Their advice should be considered alongside, not instead of, guidance from your healthcare provider, especially if you take other medications or have medical or psychiatric conditions.

Does this study show that cannabis is dangerous for people with mental health conditions?

This study did not test whether cannabis is harmful for specific conditions. It examined what dispensary staff say they would advise customers with psychiatric and medical comorbidities. The clinical evidence on cannabis and mental health is a separate and evolving question. What this study highlights is that the people most likely to advise cannabis consumers may not be well equipped to counsel on these nuances.

Do stricter state cannabis laws mean better safety advice at dispensaries?

Not necessarily, based on these data. The study found only weak and inconsistent associations between a state’s level of medical cannabis regulation and what dispensary staff reported they would advise. This suggests that regulations on paper may not translate into meaningful changes in staff behavior without additional measures like mandatory training or clinical integration programs.

Is cannabis addictive?

Yes. Cannabis use disorder is a recognized clinical diagnosis, and research consistently demonstrates that a subset of regular cannabis users develops dependence. The finding that 26% of surveyed dispensary staff did not believe cannabis is addictive highlights a knowledge gap that could affect the quality of safety counseling consumers receive at the point of sale.

Have thoughts on this? Share it: